Chemically Enhanced Immunogenicity of Bacteria by Supramolecular Functionalization with an Adjuvant.
bacteria
conjugation
immunology
inflammation
supramolecular chemistry
Journal
Chembiochem : a European journal of chemical biology
ISSN: 1439-7633
Titre abrégé: Chembiochem
Pays: Germany
ID NLM: 100937360
Informations de publication
Date de publication:
05 12 2022
05 12 2022
Historique:
revised:
29
09
2022
received:
29
07
2022
pubmed:
1
10
2022
medline:
25
1
2023
entrez:
30
9
2022
Statut:
ppublish
Résumé
Many pathogens blunt immune responses because they lack immunogenic structural features, which typically results in disease. Here, we show evidence suggesting that pathogen immunogenicity can be chemically enhanced. Using supramolecular host-guest chemistry, we complexed onto the surface of a poorly immunogenic bacterium (Staphylococcus aureus) a TLR7 agonist-based adjuvant. "Adjuvanted" bacteria were readily recognized by macrophages and induced a more pro-inflammatory immunophenotype. Future applications of this concept could yield treatment modalities that bolster the immune system's response to pathogenic microbes.
Identifiants
pubmed: 36177993
doi: 10.1002/cbic.202200434
pmc: PMC10098600
doi:
Substances chimiques
Adjuvants, Immunologic
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e202200434Informations de copyright
© 2022 The Authors. ChemBioChem published by Wiley-VCH GmbH.
Références
Cell Mol Life Sci. 2015 Nov;72(21):4111-26
pubmed: 26210152
J Nucl Med. 2014 Feb;55(2):308-14
pubmed: 24434293
PLoS Pathog. 2020 Sep 8;16(9):e1008799
pubmed: 32898164
Proc Natl Acad Sci U S A. 2019 Feb 26;116(9):3764-3773
pubmed: 30755523
Eur J Nucl Med. 2000 Mar;27(3):292-301
pubmed: 10774881
Chembiochem. 2022 Dec 5;23(23):e202200434
pubmed: 36177993
Mol Pharm. 2015 Jul 6;12(7):2505-16
pubmed: 26030231
Nature. 2014 Jan 9;505(7482):218-22
pubmed: 24336213
Am J Trop Med Hyg. 2021 Jan;104(1):283-293
pubmed: 33205741
Nature. 1997 Sep 11;389(6647):133-4
pubmed: 9296487
ACS Infect Dis. 2019 Jul 12;5(7):1160-1168
pubmed: 31016979
Bioconjug Chem. 2021 Mar 17;32(3):607-614
pubmed: 33621052
Sci Rep. 2017 Jan 06;7:39908
pubmed: 28057918
Nat Rev Dis Primers. 2016 Oct 27;2:16076
pubmed: 27784885
Biomater Sci. 2020 Jul 7;8(13):3712-3719
pubmed: 32495762
Vaccines (Basel). 2015 Apr 16;3(2):320-43
pubmed: 26343190
Bioconjug Chem. 2016 Oct 19;27(10):2372-2385
pubmed: 27583777
J Control Release. 2019 Jan 10;293:126-134
pubmed: 30485797
PLoS Pathog. 2015 Sep 14;11(9):e1005162
pubmed: 26367394
Science. 2013 Sep 20;341(6152):1359-65
pubmed: 23929949
Theranostics. 2018 Mar 23;8(9):2377-2386
pubmed: 29721086
N Engl J Med. 2009 Jul 30;361(5):468-77
pubmed: 19641203
ACS Infect Dis. 2020 Jul 10;6(7):1734-1744
pubmed: 32364374
Nature. 2017 Feb 23;542(7642):445-449
pubmed: 28199305
Bull Exp Biol Med. 2021 Feb;170(4):415-419
pubmed: 33713227
Lancet Infect Dis. 2017 May;17(5):498-509
pubmed: 28216244
Pathogens. 2015 Nov 27;4(4):826-68
pubmed: 26633519
Biomaterials. 2017 Oct;141:296-313
pubmed: 28709020
ACS Nano. 2013 May 28;7(5):3912-25
pubmed: 23590591
Nature. 2007 Oct 18;449(7164):819-26
pubmed: 17943118
Nat Microbiol. 2016 Dec 12;2:16238
pubmed: 27941860
Langmuir. 2020 Jan 14;36(1):397-408
pubmed: 31793791
Vaccine. 1998 Aug-Sep;16(14-15):1391-5
pubmed: 9711777
Front Immunol. 2021 Jan 19;11:620339
pubmed: 33542723